Double-Drug attack on tough lung cancer mutation

NCT ID NCT05375994

Completed Disease control Sponsor: Verastem, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests whether combining two targeted drugs, avutometinib and adagrasib, can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried a KRAS G12C inhibitor and seen their cancer worsen. The trial first finds the safest dose of the combination, then checks how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avutometinib and adagrasib
What this could lead to: If successful, this combination could offer a new treatment option for people with KRAS G12C-mutant lung cancer whose disease has progressed after other therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits and risks are not yet fully known. The combination may cause side effects or may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lung cancer lung neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER KRAS ACTIVATING MUTATION MALIGNANT NEOPLASM OF LUNG MALIGNANT NEOPLASTIC DISEASE METASTATIC CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Mayo Clinic Cancer Center

Jacksonville, Florida, 32224, United States
Mayo Clinic Cancer Center

Rochester, Minnesota, 55905, United States
Medical College Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
UCSF Thoracic Oncology

San Francisco, California, 94158, United States
University of Colorado Hospital Anschutz Cancer Pavllion

Aurora, Colorado, 80045, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 275514, United States
Virginia Cancer Specialists, NEXT Oncology

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.